Breaking News: Cellectis Successfully Completes Global Offering and Underwriters Exercise Option to Purchase Additional Shares
Description:
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today: the initial closing on February 7, 2023 of the previously announced underwritten global offering by way of […]. The post Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
Impact on Individuals:
Success in completing the global offering and underwriters exercising their option to purchase additional shares shows the trust and confidence investors have in Cellectis and its potential for growth. This news could positively impact individual investors who have invested in the company, potentially resulting in increased stock value and returns on their investment.
Impact on the World:
For the world, this news signifies a significant milestone in the field of biotechnology and gene-editing. Cellectis’ success in raising capital through the offering and underwriters exercising their option demonstrates the importance and potential of innovative cell and gene therapies in saving lives and advancing medical science.
Conclusion:
Overall, the completion of the global offering and underwriters exercising their option is a major achievement for Cellectis and the biotechnology industry as a whole. This success not only benefits investors but also opens up new possibilities for life-saving treatments and advancements in gene-editing technology.
